STARSOURCE MULTITRADE LIMITED — Earnings Release 2026

May 30, 2026

STARSOURCE MULTITRADE LIMITED

(Formerly known as Chemo Pharma Laboratories Limited)

(CIN: L46900MH1942PLC003556)

STARSOURCE MULTITRADE LIMITED

Date: May 30, 2026

To,

Bombay Stock Exchange Limited

Department of Corporate Services,

25th Floor, P. J. Towers, Dalal Street,

Mumbai-400001

Script Id: 506365

ISIN: INE320M01019

Subject: Submission of Newspaper Advertisement of Audited Financial Results for the

Quarter & Year Ended March 31, 2026, of the Company.

Dear Sir,

Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of the newspaper advertisement pertaining to Audited Financial Results of the Company for the Quarter & Year Ended March 31, 2026.

Business Standard on May 30, 2026.

Mumbai Lakshdeep on May 30, 2026.

The aforesaid information is also available on website of the company.

The same may please be taken on record.

Thanking You.

Yours Faithfully,

FOR STARSOURCE MULTITRADE LIMITED

(Formerly known as CHEMO PHARMA LABORATORIES LIMITED)

Mehta Ruchit

RUCHIT MEHTA

Managing Director & Chief Executive Officer

DIN: 08810586

Registered Office: 5 - Kumud Apartment CHS Ltd, Karnik Road, Chikan Ghar, Kalyan, - 421301, India

Corporate Headquarters: 1016, North Plaza, Near D Mart, Motera, Ahmedabad- 380005, India

Ph: +91-22-22078381 / 82 | Fax: +91-22-22074294

Email: chemopharmalaboratorieslimited@gmail.com | www.starsourcemultitrade.com

---

रानिकर, दि. ३० मे २०२६

पृष्ठ २

ANUPAR FINSERY LIMITED

Reg. NR. 102, Corporate Section 103, Private First, Mumbai, 2021-22
नं. 102/0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000

Contract of Operations Auditors Financial Results for Quarter and Year ended December, 2020
Particulars	Gross	Gross	Gross
	£0,000	£0,000	£0,000
GST	2,000	2,000	2,000
GST (GST) Taxes for Revenue (Dollars) Tax	20.78	20.78	200.78
GST (GST) Taxes for Revenue (Dollars) Tax (per share)	20.78	20.78	200.78
GST (GST) Per share (per share) (per share)	20.78	20.78	200.78
GST (GST) Per share (per share) (per share)	20.78	20.78	200.78

GST (GST) (GST) (per share)

GST (GST) (GST) (per share)

GST (GST) (GST) (per share)	GST (GST) (GST) (per share)
GST (GST) (GST) (per share)	GST (GST) (GST) (per share)

GST (GST) (GST) (per share)

GST (GST) (GST) (per share)

GST (GST) (GST) (per share)	GST (GST) (GST) (per share)

GST (GST) (GST) (per share)

GST (GST) (GST) (per share)

GST (GST) (GST) (per share)

GST (GST) (GST) (per share)

GST (GST) (GST) (per share)

GST (GST) (GST) (per share)

GST (GST) (GST) (per share)

GST (GST) (GST) (per share)

GST (GST) (GST) (per share)

GST (GST) (GST) (per share)

GST (GST) (GST) (per share)

GST (GST) (GST) (per share)

GST (GST) (GST) (per share)

GST (GST) (GST) (per share)

**GST (GST) (GST) (per share)

GST (GST) (GST) (per share)

GST (GST) (GST) (per share)

GST (GST) (GST) (per share)

GST (GST) (GST) (per share)

GST (GST) (GST) (per share)

GST (GST) (GST) (per share)

GST (GST) (GST) (per share)

GST (GST) (GST) (per share)

**GST (GST) (GST) (per share)

---

Business Standard NUMBER | SATURDAY, 30 MAY 2026

13

NATH INDUSTRIES LTD

Nath Industrial Industries Ltd., 12011, 12012, 12013, 12014, 12015, 12016, 12017, 12018, 12019, 12020, 12021, 12022

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31TH MARCH 2026

S1	Particular	Year Ended 2025			Year Ended 2026
		2025	2026	2027	2025	2026	2027
		£	£	£	£	£	£
1	Total Income from Operation (Bills)	1,000,000	1,007,764	1,007,777	1,000,000	1,007,764	1,007,777
2	Total Prices for Items, and Items (Bills)	37.50	36.77	36.69	334.50	336.27	336.27
3	Total Profit for Industry and Sales after Tax	227.50	26.77	26.77	267.50	26.77	267.50
4	Total Profit for Land Use	227.50	26.77	26.77	267.50	26.77	267.50
5	Total Comprehensive Income for the period	207.00	218.76	218.76	207.00	207.00	207.00
6	Total Income (from tax)	760.00	760.00	760.00	760.00	760.00	760.00
7	Earnings per Share in Pills 4/10 each	-7.99	3.32	1.06	3.51	3.12
8	1.5% Basis of Interest Earnings per Share in Pills 1	-7.99	0.00	1.06	0.01	1.06

The above is the report of the standard format of Quarantine Financial Report filed with the Council of Europe under Regulation 10 of the 2009 REG/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC

STARSOURCE MULTITRADE LIMITED

(Formerly known as CIEING PHARMA LABORATORIES LIMITED)

On You | LABORATORIES LIMITED

Registered Office: following Department: Co-Cip, Hwy, Box 124, Rosette Road, Chillian Place, Bulgan, D24. Phone 427 3311. Telephone: (02) 229 9591. E-mail: site@laborsetermania.com. E-mail: info@laborsetermania.com

Contact: 137 87470000

EXTRACT OF AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2026

S1	Particulars	Quarter Ended 31st			Year Ended 31st
		31st Ended 31/1/2025	31/1/2026	31st Ended 31/1/2027	31st Ended 31/1/2028	31/1/2029	31/1/2030
Bills	Total income from Operation (Bills) (in millions)	3,772	3,82	3,643,602	3,435,47	3,196,02
Net Profit (loss) for the period (defense) and tax (loss) (loss)	1,000,000	1,000,000	1,000,000	1,000,000	1,000,000	1,000,000
Net Income (from tax) (loss) (loss)	(112.72)	(89.11)	(10.01)	(10.01)	(10.01)	(10.01)
Total Revenue (loss) for the period (loss) (loss) (loss)	(112.72)	(89.11)	(10.01)	(10.01)	(10.01)	(10.01)
Net Income (loss) for the period (loss) (loss) (loss)	(112.72)	(89.11)	(10.01)	(10.01)	(10.01)	(10.01)
Net Income (loss) for the period (loss) (loss) (loss)	(112.72)	(89.11)	(10.01)	(10.01)	(10.01)	(10.01)
Net Income (loss) for the period (loss) (loss) (loss)	(112.72)	(89.11)	(10.01)	(10.01)	(10.01)	(10.01)

The above is the report of the detailed format of Quarantine and non-solidated financial statements filed with the Council of Europe under Regulation 10 of the 2009 REG/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/EC/01

FOR THE CELLS

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13

13